ArticleInvestigational new drugs2021

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.

Monica Balzarotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.